pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA
Kura Oncology
Kura Oncology is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker KURA. Primary therapeutic focus areas include Acute Myeloid Leukemia, Relapsed and/or refractory Acute Myeloid Leukem
Company details
- Status
- Public
- HQ
- 12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
- Founded
- 2014
- Employees
- 313
- Programs
- 25
- Drugs
- 14
- Patents
- 132
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 1 · other · Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors for Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma is a Phase 1 program (other) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Internal code KO-2806-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kura Oncology
- Phase
- Phase 1
- Modality
- other
- Indication
- Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma
- Status
- active
- Trials
- 1